Prepared by:
New England Medical Center EPC, Boston, MA
Investigators:
Leonidas Goudas, M.D., Ph.D.
Daniel B. Carr, M.D.
Rina Bloch, M.D.
Ethan Balk, M.D., M.P.H.
John P.A. Ioannidis, M.D.
Norma Terrin, Ph.D.
Maria Gialeli-Goudas, L.L.M.
Priscilla Chew, M.P.H.
Joseph Lau, M.D. (EPC director)
File Name Description Software Version File Size __________________________________________________________________________________________________________ 01front.doc Microsoft Word® Document MS Word® 97 SR-1 83KB 11 pages Contents: Volume 1 Title Page, Preface, Acknowledgments, Structured Abstract, Table of Contents __________________________________________________________________________________________________________ 02summ.doc Microsoft Word® Document MS Word® 97 SR-1 53KB 8 pages Contents: Summary: Overview, Reporting the Evidence, Patient Population and Settings, Methods, Findings, Key Questions, Future Research __________________________________________________________________________________________________________ 03chap1.doc Microsoft Word® Document MS Word® 97 SR-1 162KB 26 pages Contents: Chapter 1. Introduction: Overview of the Evidence Report, What is Cancer Pain?, The Epidemiology of Cancer and Cancer-related Pain, Assessment of Cancer Pain, Treatment Options for Cancer Pain, Issues in the Undertreatment of Cancer Pain, Summary __________________________________________________________________________________________________________ 04chap2.doc Microsoft Word® Document MS Word® 97 SR-1 133KB 18 pages Contents: Chapter 2. Methodology, Recruitment of Technical Experts, Patient Population Studied, Key Questions, Literature Search, Study Selection, Data Abstraction, Methods for Summarizing Results, Estimations of Drug Costs __________________________________________________________________________________________________________ 05chap3a.doc Microsoft Word® Document MS Word® 97 SR-1 235KB 43 pages Contents: Chapter 3. Results: General Observations, Findings for Specific Questions Question 1. What are the epidemiological characteristics of cancer-related pain, including pain caused by cancer, by procedures used to treat cancer, and by the side effects of cancer treatment? Question 2. What is the relative efficacy of analgesics currently used for cancer pain? Question 3. Are different formulations and routes of administration associated with different patient preferences or different efficacy rates? (first part) __________________________________________________________________________________________________________ 06chap3b.doc Microsoft Word® Document MS Word® 97 SR-1 613KB 47 pages Contents: Chapter 3. Results: Findings for Specific Questions (continued) Question 3. Are different formulations and routes of administration associated with different patient preferences or different efficacy rates? (continued) Question 4. What is the relative analgesic efficacy of palliative pharmacological (chemotherapy, biphosphonates, or calcitonin) and nonpharmacological cytotoxic or cytostatic (radiation or radionuclide) therapy? Question 5. What is the relative efficacy of current adjuvant (nonpharmacological/noninvasive) physical or psychological treatments (relaxation, massage, heat and cold, music, exercise, and so on) in the management of cancer-related pain? Question 6. What is the relative efficacy of current invasive surgical and nonsurgical treatments, such as acupuncture, nerve blocks, and neuroablation, in the treatment of cancer-related pain? __________________________________________________________________________________________________________ 07chap4.doc Microsoft Word® Document MS Word® 97 SR-1 39KB 5 pages Contents: Chapter 4. Conclusions __________________________________________________________________________________________________________ 08chap5.doc Microsoft Word® Document MS Word® 97 SR-1 36KB 4 pages Contents: Chapter 5. Future Research __________________________________________________________________________________________________________ 09ref.doc Microsoft Word® Document MS Word® 97 SR-1 19KB 1 page Contents: Note on references __________________________________________________________________________________________________________ 10meta.doc Microsoft Word® Document MS Word® 97 SR-1 29KB 3 pages Contents: Meta-Analysis of Randomized Controlled Trials __________________________________________________________________________________________________________ 11gloss.doc Microsoft Word® Document MS Word® 97 SR-1 50KB 8 pages Contents: Acronyms and Abbreviations, Glossary __________________________________________________________________________________________________________ 12biblio.doc Microsoft Word® Document MS Word® 97 SR-1 224KB 25 pages Contents: Bibliography __________________________________________________________________________________________________________ 13appab.doc Microsoft Word® Document MS Word® 97 SR-1 29KB 5 pages Contents: Appendix A. Evidence Report Staff and Technical Expert Advisory Group, Appendix B. Peer Reviewers __________________________________________________________________________________________________________ 14appc.doc Microsoft Word® Document MS Word® 97 SR-1 43KB 3 pages Contents: Appendix C. Screening Form __________________________________________________________________________________________________________ 15v2frt.doc Microsoft Word® Document MS Word® 97 SR-1 31KB 6 pages Contents: Volume 2 (Evidence Tables): Title Page, Preface, Acknowledgments, Table of Contents (list of evidence tables) __________________________________________________________________________________________________________ 16etbs-a.doc Microsoft Word® Document MS Word® 97 SR-1 522KB 106 pages Contents: Evidence Tables: Table 1. Epidemiology of Cancer Pain Summary Table 2. NSAIDs: Randomized Controlled Trials in Cancer Pain Table 3. NSAID vs. Opioid (± NSAID): Randomized Controlled Trials in Cancer Pain Table 4. Opiod vs. Opioid: Randomized Controlled Trials in Cancer Pain Table 5. Opioid Adjuvants: Randomized Controlled Trials in Cancer Pain Table 6. Miscellaneous Interventions: Randomized Controlled Trials in Cancer Pain __________________________________________________________________________________________________________ 17etbs-b.doc Microsoft Word® Document MS Word® 97 SR-1 478KB 104 pages Contents: Evidence Tables: Table 7. Biphosphonates: Randomized Controlled Trials in Cancer Pain Table 8. Chemo- or Radiotherapy: Randomized Controlled Trials in Cancer Pain Table 9. Educational-Behavioral-Psychosocial Interventions: Randomized Controlled Trials in Cancer Pain Table 10. Hypnosis: Randomized Controlled Trials in Cancer Pain Table 11. Neurolytic Celiac Plexus Block: Randomized Controlled Trials in Cancer Pain Table 12. Rhizotomy: Nonrandomized Controlled Trials in Cancer Pain Table 13. Cordotomy: Nonrandomized Controlled Trials in Cancer Pain Table 14. Adverse Events Reported During Oral Opioid Therapy of Cancer Pain: Data from Nonrandomized Studies Table 15. Adverse Events Reported During Parenteral Opioid Therapy of Cancer Pain: Data From Nonrandomized Studies Table 16. Adverse Events Reported During Transdermal Fentanyl Therapy of Cancer Pain: Data from Nonrandomized Studies Table 17. Adverse Events Reported During Spinal Opioid Therapy of Cancer Pain: Data from Nonrandomized Studies Table 18. Adverse Effects Reported During NSAID Therapy of Cancer Pain: Data from Nonrandomized and Other Studies Table 19. Adverse Effects Reported During Cancer Pain Treatment According to WHO Guidelines: Data from Nonrandomized Studies Table 20. Opioid Relative Potency Assays--Randomized Controlled Trials in Cancer Pain __________________________________________________________________________________________________________
AHRQ Publication No. 02-E002
Current as of October 2001
Internet Citation:
Management of Cancer Pain. File Inventory, Evidence Report/Technology Assessment Number 35. AHRQ Publication No. 02-E002, October 2001. Agency for Healthcare Research and Quality, Rockville, MD. http://www.ahrq.gov/clinic/capaininv.htm
Return to Evidence-based Practice
Clinical Information
AHRQ Home Page
Department of Health and Human Services